DK2776430T3 - 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists - Google Patents

Info

Publication number

DK2776430T3

DK2776430T3 DK12791862.1T DK12791862T DK2776430T3 DK 2776430 T3 DK2776430 T3 DK 2776430T3 DK 12791862 T DK12791862 T DK 12791862T DK 2776430 T3 DK2776430 T3 DK 2776430T3

Authority

DK

Denmark

Prior art keywords

triazol

benzyl

phenyl

methanone

morpholin

Prior art date

2011-11-08

Links

• Espacenet
• Global Dossier
• Discuss

• -1 1,2,3-triazol-2-yl Chemical group 0.000 title claims description 142
• 229940123730 Orexin receptor antagonist Drugs 0.000 title description 8
• 150000001875 compounds Chemical class 0.000 claims description 279
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
• 229910052739 hydrogen Inorganic materials 0.000 claims description 54
• 239000001257 hydrogen Substances 0.000 claims description 54
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 47
• 125000000217 alkyl group Chemical group 0.000 claims description 35
• 208000035475 disorder Diseases 0.000 claims description 33
• 150000002431 hydrogen Chemical group 0.000 claims description 31
• 150000003839 salts Chemical class 0.000 claims description 30
• 229910052736 halogen Inorganic materials 0.000 claims description 27
• 150000002367 halogens Chemical class 0.000 claims description 27
• 208000019901 Anxiety disease Diseases 0.000 claims description 22
• 125000001153 fluoro group Chemical group F* 0.000 claims description 22
• 206010012335 Dependence Diseases 0.000 claims description 21
• 239000003814 drug Substances 0.000 claims description 17
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
• 125000001424 substituent group Chemical group 0.000 claims description 16
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
• 201000010099 disease Diseases 0.000 claims description 14
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 13
• 125000004432 carbon atom Chemical group C* 0.000 claims description 13
• 125000003709 fluoroalkyl group Chemical group 0.000 claims description 13
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 13
• 208000019022 Mood disease Diseases 0.000 claims description 12
• 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
• 208000019454 Feeding and Eating disease Diseases 0.000 claims description 11
• 125000001072 heteroaryl group Chemical group 0.000 claims description 11
• 239000011737 fluorine Chemical group 0.000 claims description 10
• 229910052731 fluorine Inorganic materials 0.000 claims description 10
• 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 10
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 10
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 9
• 230000002265 prevention Effects 0.000 claims description 9
• 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims description 9
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 9
• 125000001425 triazolyl group Chemical group 0.000 claims description 9
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 8
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
• 125000001544 thienyl group Chemical group 0.000 claims description 8
• 125000002971 oxazolyl group Chemical group 0.000 claims description 7
• 125000004076 pyridyl group Chemical group 0.000 claims description 7
• 125000000335 thiazolyl group Chemical group 0.000 claims description 7
• 208000027559 Appetite disease Diseases 0.000 claims description 6
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 6
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
• LZAJTUGFVUQFAB-LJQANCHMSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 LZAJTUGFVUQFAB-LJQANCHMSA-N 0.000 claims description 4
• 125000004950 trifluoroalkyl group Chemical group 0.000 claims description 4
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
• AKVDRUIVHSDXNM-GOSISDBHSA-N [(3r)-3-[(4-chloro-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=CN=2)Cl)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 AKVDRUIVHSDXNM-GOSISDBHSA-N 0.000 claims description 3
• OREIPZHDUFKPTP-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=CN=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 OREIPZHDUFKPTP-LJQANCHMSA-N 0.000 claims description 3
• APWITTXYMQNNTN-LJQANCHMSA-N [(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C(F)(F)F)C(C=1)=CC=CC=1N1N=CC=N1 APWITTXYMQNNTN-LJQANCHMSA-N 0.000 claims description 3
• HCNLIVZSGOZAEH-LJQANCHMSA-N [2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 HCNLIVZSGOZAEH-LJQANCHMSA-N 0.000 claims description 3
• ONVKTAGSXCPXIK-LJQANCHMSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)Cl)C(C=1)=CC=CC=1N1N=CC=N1 ONVKTAGSXCPXIK-LJQANCHMSA-N 0.000 claims description 3
• CLOOLVHJLDFMDV-LJQANCHMSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)Cl)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 CLOOLVHJLDFMDV-LJQANCHMSA-N 0.000 claims description 3
• 239000000460 chlorine Substances 0.000 claims description 3
• 229910052801 chlorine Inorganic materials 0.000 claims description 3
• 238000004519 manufacturing process Methods 0.000 claims description 3
• GTTJINSRAWFIHD-WIYYLYMNSA-N [(2R,5R)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)C1=NC=CC=N1)C(=O)C1=C(C=CC=C1)N1N=CC=N1 GTTJINSRAWFIHD-WIYYLYMNSA-N 0.000 claims description 2
• SNOAPCQTEZAFRK-VQIMIIECSA-N [(2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=CC=C2)N2N=CC=N2)C)C=C(C=C1)N1N=CC=N1 SNOAPCQTEZAFRK-VQIMIIECSA-N 0.000 claims description 2
• BAHLPIRZKQNNOE-GOSISDBHSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound ClC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 BAHLPIRZKQNNOE-GOSISDBHSA-N 0.000 claims description 2
• PHEQMGRTEIENAJ-LJQANCHMSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c(c1)-n1nccn1 PHEQMGRTEIENAJ-LJQANCHMSA-N 0.000 claims description 2
• NSPDBKKKFMEMRB-HXUWFJFHSA-N [(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 NSPDBKKKFMEMRB-HXUWFJFHSA-N 0.000 claims description 2
• FYQCTNQQQSRWPV-HXUWFJFHSA-N [(3r)-3-[(3-pyridazin-3-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CN=N1 FYQCTNQQQSRWPV-HXUWFJFHSA-N 0.000 claims description 2
• RHBCBAZYIYZIMR-HXUWFJFHSA-N [(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 RHBCBAZYIYZIMR-HXUWFJFHSA-N 0.000 claims description 2
• YHWXLTYWQSZIKW-HXUWFJFHSA-N [(3r)-3-[(3-thiophen-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CS1 YHWXLTYWQSZIKW-HXUWFJFHSA-N 0.000 claims description 2
• CZERAVZVKNLXOP-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyrazin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=NC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 CZERAVZVKNLXOP-LJQANCHMSA-N 0.000 claims description 2
• HZTIXYMNAITACJ-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)N2N=CC=C2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 HZTIXYMNAITACJ-LJQANCHMSA-N 0.000 claims description 2
• FURKPFKLIIWSMR-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-pyridazin-3-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=NC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 FURKPFKLIIWSMR-LJQANCHMSA-N 0.000 claims description 2
• KKEOYRYRWVSPJZ-HXUWFJFHSA-N [(3r)-3-[(4-methoxy-3-pyridin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2N=CC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 KKEOYRYRWVSPJZ-HXUWFJFHSA-N 0.000 claims description 2
• OLMUIMIZDWOYII-OAQYLSRUSA-N [(3r)-3-[(4-methoxy-3-pyridin-3-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2C=NC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 OLMUIMIZDWOYII-OAQYLSRUSA-N 0.000 claims description 2
• PNGWMHMVJINNEB-LJQANCHMSA-N [(3r)-3-[(4-methoxy-3-thiophen-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2SC=CC=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 PNGWMHMVJINNEB-LJQANCHMSA-N 0.000 claims description 2
• HVGUQKUDHLWJBC-GOSISDBHSA-N [(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)N2N=CC=N2)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 HVGUQKUDHLWJBC-GOSISDBHSA-N 0.000 claims description 2
• ORPRTCJZBDNPEM-LJQANCHMSA-N [(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 ORPRTCJZBDNPEM-LJQANCHMSA-N 0.000 claims description 2
• CSOMRAVZERRDSF-GOSISDBHSA-N [(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 CSOMRAVZERRDSF-GOSISDBHSA-N 0.000 claims description 2
• HVSHPQWTNYULCB-LJQANCHMSA-N [(3r)-3-[[3-(1,3-oxazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CO1 HVSHPQWTNYULCB-LJQANCHMSA-N 0.000 claims description 2
• FYEWZQAALXXWSM-LJQANCHMSA-N [(3r)-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CS1 FYEWZQAALXXWSM-LJQANCHMSA-N 0.000 claims description 2
• WXVVKTBDFXUAHG-OAQYLSRUSA-N [(3r)-3-[[3-(4-methylpyrimidin-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC=NC(C=2C=C(C[C@H]3N(CCOC3)C(=O)C=3C(=CC=CC=3)N3N=CC=N3)C=CC=2)=N1 WXVVKTBDFXUAHG-OAQYLSRUSA-N 0.000 claims description 2
• GHEMSERNBZGDLL-GOSISDBHSA-N [(3r)-3-[[4-methoxy-3-(1,3-oxazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2OC=CN=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 GHEMSERNBZGDLL-GOSISDBHSA-N 0.000 claims description 2
• CMSWWEXLVMHQNL-GOSISDBHSA-N [(3r)-3-[[4-methoxy-3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2SC=CN=2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 CMSWWEXLVMHQNL-GOSISDBHSA-N 0.000 claims description 2
• HCNLIVZSGOZAEH-IBGZPJMESA-N [2-(triazol-2-yl)phenyl]-[(3s)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 HCNLIVZSGOZAEH-IBGZPJMESA-N 0.000 claims description 2
• IEHBRXSPEXUDES-AUSIDOKSSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 IEHBRXSPEXUDES-AUSIDOKSSA-N 0.000 claims description 2
• SWDMQWHTMPUUHA-XMSQKQJNSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C(C)=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 SWDMQWHTMPUUHA-XMSQKQJNSA-N 0.000 claims description 2
• XOKDIMBLNFVNEH-HXUWFJFHSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1N1N=CC=N1 XOKDIMBLNFVNEH-HXUWFJFHSA-N 0.000 claims description 2
• WBUINJWSFUWINW-HXUWFJFHSA-N [3,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=C(C)C=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 WBUINJWSFUWINW-HXUWFJFHSA-N 0.000 claims description 2
• YLJVEPVMPPEJBJ-VQIMIIECSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(Cl)C=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 YLJVEPVMPPEJBJ-VQIMIIECSA-N 0.000 claims description 2
• IGNKAYVYFKMOBL-GOSISDBHSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)Cl)C(C=1)=CC=CC=1N1N=CC=N1 IGNKAYVYFKMOBL-GOSISDBHSA-N 0.000 claims description 2
• BTNLZELUPKRKLO-HXUWFJFHSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C=1)=CC=CC=1C=1N=CON=1 BTNLZELUPKRKLO-HXUWFJFHSA-N 0.000 claims description 2
• QBNJEFPDYRBZMY-SIKLNZKXSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=CC(C)=C(C)C=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 QBNJEFPDYRBZMY-SIKLNZKXSA-N 0.000 claims description 2
• UIELPQGRXTWUBL-OXQOHEQNSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(Cl)=CC=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 UIELPQGRXTWUBL-OXQOHEQNSA-N 0.000 claims description 2
• CZXWCWCRILWJKE-QGZVFWFLSA-N [4-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C2=NOC=N2)OC)OCCN1C(=O)C1=CC=C(F)C=C1N1N=CC=N1 CZXWCWCRILWJKE-QGZVFWFLSA-N 0.000 claims description 2
• MRZOKJFVVJMJLC-LJQANCHMSA-N [4-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)OC)C(C=1)=CC=CC=1N1N=CC=N1 MRZOKJFVVJMJLC-LJQANCHMSA-N 0.000 claims description 2
• SMVHMTBUOLIQMT-OXQOHEQNSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 SMVHMTBUOLIQMT-OXQOHEQNSA-N 0.000 claims description 2
• LAINVSFGRYRKDA-HXUWFJFHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)Cl)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 LAINVSFGRYRKDA-HXUWFJFHSA-N 0.000 claims description 2
• SYLDJPVOGVSYAI-HXUWFJFHSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)F)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 SYLDJPVOGVSYAI-HXUWFJFHSA-N 0.000 claims description 2
• GEVLHZAYQOXANJ-HXUWFJFHSA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)OC)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 GEVLHZAYQOXANJ-HXUWFJFHSA-N 0.000 claims description 2
• CWBKFZFKBHRMPJ-LJQANCHMSA-N [5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)OC)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 CWBKFZFKBHRMPJ-LJQANCHMSA-N 0.000 claims description 2
• GSBLIJRKLPIUPS-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CC=N1 GSBLIJRKLPIUPS-OAQYLSRUSA-N 0.000 claims description 2
• KQPLEQHOKPZPHW-HSZRJFAPSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridin-4-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=NC=C1 KQPLEQHOKPZPHW-HSZRJFAPSA-N 0.000 claims description 2
• JHOLYWCJSQKKLV-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 JHOLYWCJSQKKLV-OAQYLSRUSA-N 0.000 claims description 2
• ZFYSWSAVTSDYNI-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-1-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=CN=N1 ZFYSWSAVTSDYNI-HXUWFJFHSA-N 0.000 claims description 2
• JQRRTXWUYXPFEP-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 JQRRTXWUYXPFEP-HXUWFJFHSA-N 0.000 claims description 2
• 239000004480 active ingredient Substances 0.000 claims description 2
• 229910052799 carbon Inorganic materials 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
• UJDZZHFYTLBQSA-FGZHOGPDSA-N [(2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C(C)[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)C(=O)C1=C(C=C(C=C1)C)N1N=CC=N1 UJDZZHFYTLBQSA-FGZHOGPDSA-N 0.000 claims 1
• SBZFLVKAWPYIDI-FGZHOGPDSA-N [(2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C(C)[C@@H]1CN([C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)C(=O)C1=C(C=CC(=C1)C)N1N=CC=N1 SBZFLVKAWPYIDI-FGZHOGPDSA-N 0.000 claims 1
• STUGMTDSOKPRBQ-WIYYLYMNSA-N [(2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C[C@@H]1CN([C@H](Cc2cc(ccc2F)-c2ncccn2)CO1)C(=O)c1cccc(C)c1-n1nccn1 STUGMTDSOKPRBQ-WIYYLYMNSA-N 0.000 claims 1
• HYSRABRBUHZYQJ-WIYYLYMNSA-N [(2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C)C=C(C=C1)C1=NC=CC=N1 HYSRABRBUHZYQJ-WIYYLYMNSA-N 0.000 claims 1
• AEIDDRZWBROWDG-WIYYLYMNSA-N [(2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2C(=O)C2=C(C=CC(=C2)C)N2N=CC=N2)C)C=C(C=C1)C1=NC=CC=N1 AEIDDRZWBROWDG-WIYYLYMNSA-N 0.000 claims 1
• KJPCUIQPIJYTDA-HXUWFJFHSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3,4-dimethyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c(c1C)-n1nccn1 KJPCUIQPIJYTDA-HXUWFJFHSA-N 0.000 claims 1
• FIPXBPYXRCPALA-LJQANCHMSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound Cc1cccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c1-n1nccn1 FIPXBPYXRCPALA-LJQANCHMSA-N 0.000 claims 1
• HZYFRDSVQFDLHM-LJQANCHMSA-N [(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound ClC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC(=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 HZYFRDSVQFDLHM-LJQANCHMSA-N 0.000 claims 1
• YNLXALPSUPUEOW-GOSISDBHSA-N [(3R)-3-[[2-fluoro-3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound FC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C=CC=C1N1N=CC=N1 YNLXALPSUPUEOW-GOSISDBHSA-N 0.000 claims 1
• HYFRBSMLWUEXKY-GOSISDBHSA-N [(3R)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-4-(trifluoromethyl)phenyl]methanone Chemical compound Fc1ccc(cc1C[C@@H]1COCCN1C(=O)c1ccc(cc1-n1nccn1)C(F)(F)F)-n1nccn1 HYFRBSMLWUEXKY-GOSISDBHSA-N 0.000 claims 1
• BNXAFMJKKZGLDN-LJQANCHMSA-N [(3R)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[5-methoxy-4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound COc1cc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2F)-n2nccn2)c(cc1C)-n1nccn1 BNXAFMJKKZGLDN-LJQANCHMSA-N 0.000 claims 1
• SKTHZCLPOHWFMH-HXUWFJFHSA-N [(3R)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 SKTHZCLPOHWFMH-HXUWFJFHSA-N 0.000 claims 1
• PNBXBOOTVNVZSH-LJQANCHMSA-N [(3R)-3-[[3-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound FC=1C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C(C1)N1N=CC=N1 PNBXBOOTVNVZSH-LJQANCHMSA-N 0.000 claims 1
• KDSFEYCWXQWBSK-HXUWFJFHSA-N [(3r)-3-[(2-fluoro-5-pyridazin-3-ylphenyl)methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1C1=CC=CN=N1 KDSFEYCWXQWBSK-HXUWFJFHSA-N 0.000 claims 1
• VLMPYJVCPJRPBH-HXUWFJFHSA-N [(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 VLMPYJVCPJRPBH-HXUWFJFHSA-N 0.000 claims 1
• LUSDGIQGCBLNQS-HXUWFJFHSA-N [(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 LUSDGIQGCBLNQS-HXUWFJFHSA-N 0.000 claims 1
• QIKVTMHZHYXNDE-HXUWFJFHSA-N [(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 QIKVTMHZHYXNDE-HXUWFJFHSA-N 0.000 claims 1
• LZJVNRGGFLKPHX-JOCHJYFZSA-N [(3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2C)N2N=CC=C2)OCCN1C(=O)C1=CC=CC(C)=C1N1N=CC=N1 LZJVNRGGFLKPHX-JOCHJYFZSA-N 0.000 claims 1
• ZVAZIIXJYBKGIK-JOCHJYFZSA-N [(3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)C)=CC=1N1C=CC=N1 ZVAZIIXJYBKGIK-JOCHJYFZSA-N 0.000 claims 1
• WOWXUSLEOFOYDZ-JOCHJYFZSA-N [(3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C(=CC=1)C)=CC=1N1C=CC=N1 WOWXUSLEOFOYDZ-JOCHJYFZSA-N 0.000 claims 1
• CXGGFUAERWUYLI-GOSISDBHSA-N [(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-4-(trifluoromethyl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C(F)(F)F)C(C=1)=CC=CC=1C=1N=CON=1 CXGGFUAERWUYLI-GOSISDBHSA-N 0.000 claims 1
• KXYYELXHLGICGL-HXUWFJFHSA-N [(3r)-3-[[3-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[3-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C=1)=CC(Cl)=CC=1N1N=CC=N1 KXYYELXHLGICGL-HXUWFJFHSA-N 0.000 claims 1
• LHHCFJSPYOKYPR-HXUWFJFHSA-N [(3r)-3-[[3-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC(Cl)=CC=1N1N=CC=N1 LHHCFJSPYOKYPR-HXUWFJFHSA-N 0.000 claims 1
• BQSVOWNLNGKKOQ-MRXNPFEDSA-N [(3r)-3-[[4-chloro-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C2=NOC=N2)Cl)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 BQSVOWNLNGKKOQ-MRXNPFEDSA-N 0.000 claims 1
• HUPRZYCCDOZRQO-QGZVFWFLSA-N [(3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C2=NOC=N2)OC)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 HUPRZYCCDOZRQO-QGZVFWFLSA-N 0.000 claims 1
• XLQIWSDYHVBNIH-LJQANCHMSA-N [(3r)-3-[[4-methyl-3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)N2N=CC=N2)C)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 XLQIWSDYHVBNIH-LJQANCHMSA-N 0.000 claims 1
• AHOIUZFUVOTFMM-QGZVFWFLSA-N [2-fluoro-3-methoxy-6-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)OC)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 AHOIUZFUVOTFMM-QGZVFWFLSA-N 0.000 claims 1
• STZDRKWMTBHWJI-GOSISDBHSA-N [2-fluoro-3-methyl-6-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)C)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 STZDRKWMTBHWJI-GOSISDBHSA-N 0.000 claims 1
• LCWVNVDNSNRWAR-QGZVFWFLSA-N [2-fluoro-6-(triazol-2-yl)phenyl]-[(3R)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound Fc1ccc(cc1C[C@@H]1COCCN1C(=O)c1c(F)cccc1-n1nccn1)-n1nccn1 LCWVNVDNSNRWAR-QGZVFWFLSA-N 0.000 claims 1
• KZQTUXCCKNLSIX-XMSQKQJNSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 KZQTUXCCKNLSIX-XMSQKQJNSA-N 0.000 claims 1
• DADWYMXJDHTELJ-LJQANCHMSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1C=1N=CON=1 DADWYMXJDHTELJ-LJQANCHMSA-N 0.000 claims 1
• QEFAZNLAURABKO-OAQYLSRUSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C=1)=CC=CC=1N1N=CC=N1 QEFAZNLAURABKO-OAQYLSRUSA-N 0.000 claims 1
• YGTXKPMZPUBWGV-QGZVFWFLSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound Clc1ccc(cc1C[C@@H]1COCCN1C(=O)c1cccc(Cl)c1-n1nccn1)-n1nccn1 YGTXKPMZPUBWGV-QGZVFWFLSA-N 0.000 claims 1
• HMJZZKHOLAJQCJ-PGRDOPGGSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(2S,3R)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C[C@H]1[C@H](N(CCO1)C(=O)C1=C(C(=CC=C1)C)N1N=CC=N1)CC1=CC(=CC=C1)N1N=CC=N1 HMJZZKHOLAJQCJ-PGRDOPGGSA-N 0.000 claims 1
• WRLVGTRMEZGZFE-WIYYLYMNSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=C(C)C=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 WRLVGTRMEZGZFE-WIYYLYMNSA-N 0.000 claims 1
• OQHUOGSZVADTEQ-OAQYLSRUSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound CC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C(=CC=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 OQHUOGSZVADTEQ-OAQYLSRUSA-N 0.000 claims 1
• UGPJDNRZMHMMDB-LJQANCHMSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C=1)=CC=CC=1C=1N=CON=1 UGPJDNRZMHMMDB-LJQANCHMSA-N 0.000 claims 1
• NERGNQKZFUFHEN-HXUWFJFHSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=CC=C(C=1N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 NERGNQKZFUFHEN-HXUWFJFHSA-N 0.000 claims 1
• UFYCDZYJXMCYQI-WIYYLYMNSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3r,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@H](N1C(=O)C=1C(=C(C)C=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 UFYCDZYJXMCYQI-WIYYLYMNSA-N 0.000 claims 1
• UFYCDZYJXMCYQI-GHTZIAJQSA-N [3-methyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=C(C)C=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 UFYCDZYJXMCYQI-GHTZIAJQSA-N 0.000 claims 1
• KOVCCWGOMZVONL-MRXNPFEDSA-N [4,5-difluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)F)F)C(C=1)=CC=CC=1C=1N=CON=1 KOVCCWGOMZVONL-MRXNPFEDSA-N 0.000 claims 1
• HJRBUDPCLJIXSQ-LJQANCHMSA-N [4,5-dimethoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)OC)OC)C(C=1)=CC=CC=1N1N=CC=N1 HJRBUDPCLJIXSQ-LJQANCHMSA-N 0.000 claims 1
• QGLAATQFBFNUCL-DENIHFKCSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(C)=C(C)C=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 QGLAATQFBFNUCL-DENIHFKCSA-N 0.000 claims 1
• DPAIDVFQHYLKSX-HXUWFJFHSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1N1N=CC=N1 DPAIDVFQHYLKSX-HXUWFJFHSA-N 0.000 claims 1
• WWEKFLWFASRPJA-OAQYLSRUSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C=1)=CC=CC=1N1N=CC=N1 WWEKFLWFASRPJA-OAQYLSRUSA-N 0.000 claims 1
• DLTFUAAXCYAOLA-HXUWFJFHSA-N [4,5-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[4-methyl-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)C)C(C=1)=CC=C(C)C=1C=1N=CON=1 DLTFUAAXCYAOLA-HXUWFJFHSA-N 0.000 claims 1
• AOIUNCRFTKYDNL-GOSISDBHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-chloro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound Clc1ccc(C(=O)N2CCOC[C@H]2Cc2cc(ccc2Cl)-n2nccn2)c(c1)-n1nccn1 AOIUNCRFTKYDNL-GOSISDBHSA-N 0.000 claims 1
• IUBQIPSNLRGHJH-GOSISDBHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)Cl)C(C=1)=CC=CC=1C=1N=CON=1 IUBQIPSNLRGHJH-GOSISDBHSA-N 0.000 claims 1
• JRGASLNNEVZZRN-QGZVFWFLSA-N [4-chloro-5-methoxy-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)Cl)OC)C(C(=CC=1)F)=CC=1N1N=CC=N1 JRGASLNNEVZZRN-QGZVFWFLSA-N 0.000 claims 1
• QCNZPQHXWUCBEP-LJQANCHMSA-N [4-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)F)C(C=1)=CC=CC=1N1N=CC=N1 QCNZPQHXWUCBEP-LJQANCHMSA-N 0.000 claims 1
• WOQOCTXBEIMJQF-XMSQKQJNSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2r,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@@H]1C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 WOQOCTXBEIMJQF-XMSQKQJNSA-N 0.000 claims 1
• XDAZJJGYLDZHNW-WIYYLYMNSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 XDAZJJGYLDZHNW-WIYYLYMNSA-N 0.000 claims 1
• WOQOCTXBEIMJQF-PGRDOPGGSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2s,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@H]1C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 WOQOCTXBEIMJQF-PGRDOPGGSA-N 0.000 claims 1
• XDAZJJGYLDZHNW-GHTZIAJQSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(2s,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@@H](OC1)C)C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 XDAZJJGYLDZHNW-GHTZIAJQSA-N 0.000 claims 1
• QRQCKASOXSZLKU-OAQYLSRUSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3R)-3-[[2-methyl-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound CC1=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=C(C=C2)C)N2N=CC=N2)C=C(C=C1)N1N=CC=N1 QRQCKASOXSZLKU-OAQYLSRUSA-N 0.000 claims 1
• WYFQHYNFGVNXFG-OAQYLSRUSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC=CC=1N1C=CC=N1 WYFQHYNFGVNXFG-OAQYLSRUSA-N 0.000 claims 1
• DCMSTVVYTKCBDX-LJQANCHMSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC=CC=1C=1N=CON=1 DCMSTVVYTKCBDX-LJQANCHMSA-N 0.000 claims 1
• GKPHAIOJCHBZCT-HXUWFJFHSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 GKPHAIOJCHBZCT-HXUWFJFHSA-N 0.000 claims 1
• FCVGUKJNRFNLDS-WIYYLYMNSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3r,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@H](N1C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 FCVGUKJNRFNLDS-WIYYLYMNSA-N 0.000 claims 1
• FCVGUKJNRFNLDS-GHTZIAJQSA-N [4-methyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=CC(C)=CC=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 FCVGUKJNRFNLDS-GHTZIAJQSA-N 0.000 claims 1
• VZSCFYBYGCGNNT-DNVCBOLYSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C(=CC=1)F)=CC=1N1N=CC=N1 VZSCFYBYGCGNNT-DNVCBOLYSA-N 0.000 claims 1
• IBFHVKISQVPMHU-GOSISDBHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)Cl)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 IBFHVKISQVPMHU-GOSISDBHSA-N 0.000 claims 1
• TVALGRAHOLPKKR-GOSISDBHSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)F)N1N=CC=N1)C(C=1)=CC=CC=1C=1N=CON=1 TVALGRAHOLPKKR-GOSISDBHSA-N 0.000 claims 1
• HGBYUIVSHGPNIW-LJQANCHMSA-N [5-fluoro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)F)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 HGBYUIVSHGPNIW-LJQANCHMSA-N 0.000 claims 1
• TXOLBWQUYQXATH-HXUWFJFHSA-N [5-methoxy-4-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C=C(C(=CC=1N1N=CC=N1)C)OC)C(C=1)=CC=CC=1N1N=CC=N1 TXOLBWQUYQXATH-HXUWFJFHSA-N 0.000 claims 1
• DZMITGRLYMROFK-FDDCHVKYSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2s,3r)-2-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(CCO[C@H]1C)C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 DZMITGRLYMROFK-FDDCHVKYSA-N 0.000 claims 1
• WQKDFCTZXNZINF-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyrazin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CN=CC=N1 WQKDFCTZXNZINF-OAQYLSRUSA-N 0.000 claims 1
• QZXHCJASGVSEHH-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridazin-3-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CN=N1 QZXHCJASGVSEHH-OAQYLSRUSA-N 0.000 claims 1
• QQGJVBSRNSZDOO-JOCHJYFZSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CC=N1 QQGJVBSRNSZDOO-JOCHJYFZSA-N 0.000 claims 1
• SBTZFUJQUNEVMJ-HSZRJFAPSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-pyridin-3-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CN=C1 SBTZFUJQUNEVMJ-HSZRJFAPSA-N 0.000 claims 1
• SPVLNBKCMBRTPX-OAQYLSRUSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(3-thiophen-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=CC=CS1 SPVLNBKCMBRTPX-OAQYLSRUSA-N 0.000 claims 1
• PUZJVVRRRYQHLK-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,2,4-triazol-1-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1C=NC=N1 PUZJVVRRRYQHLK-HXUWFJFHSA-N 0.000 claims 1
• ZGEVFIAJYRECKD-HXUWFJFHSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CS1 ZGEVFIAJYRECKD-HXUWFJFHSA-N 0.000 claims 1
• ARAHFWCCUIXFBE-GHTZIAJQSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(3s,5r)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COC[C@@H](N1C(=O)C=1C(=CC=C(C)C=1)N1N=CC=N1)C)C(C=1)=CC=CC=1N1N=CC=N1 ARAHFWCCUIXFBE-GHTZIAJQSA-N 0.000 claims 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 125
• 238000000034 method Methods 0.000 description 115
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 101
• 238000006243 chemical reaction Methods 0.000 description 72
• 102000002512 Orexin Human genes 0.000 description 59
• 108060005714 orexin Proteins 0.000 description 59
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 54
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 50
• 239000011541 reaction mixture Substances 0.000 description 46
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
• 239000000243 solution Substances 0.000 description 38
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
• 239000000203 mixture Substances 0.000 description 34
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
• 239000002904 solvent Substances 0.000 description 28
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 26
• 239000000284 extract Substances 0.000 description 26
• 239000000543 intermediate Substances 0.000 description 26
• 239000007787 solid Substances 0.000 description 26
• 229910052786 argon Inorganic materials 0.000 description 25
• 239000000725 suspension Substances 0.000 description 24
• 210000004556 brain Anatomy 0.000 description 23
• 239000012043 crude product Substances 0.000 description 23
• 239000010410 layer Substances 0.000 description 23
• 235000019439 ethyl acetate Nutrition 0.000 description 22
• 125000003545 alkoxy group Chemical group 0.000 description 20
• UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 20
• 230000015654 memory Effects 0.000 description 20
• 239000012267 brine Substances 0.000 description 19
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
• 239000008346 aqueous phase Substances 0.000 description 18
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
• 230000015572 biosynthetic process Effects 0.000 description 17
• 230000035882 stress Effects 0.000 description 17
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
• 238000000746 purification Methods 0.000 description 16
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
• 238000003818 flash chromatography Methods 0.000 description 15
• 238000002360 preparation method Methods 0.000 description 15
• 102000005962 receptors Human genes 0.000 description 15
• 108020003175 receptors Proteins 0.000 description 15
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 14
• 239000003480 eluent Substances 0.000 description 14
• 238000007429 general method Methods 0.000 description 14
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
• 238000004128 high performance liquid chromatography Methods 0.000 description 13
• 230000007958 sleep Effects 0.000 description 13
• 208000019116 sleep disease Diseases 0.000 description 13
• 238000005160 1H NMR spectroscopy Methods 0.000 description 12
• 229910052796 boron Inorganic materials 0.000 description 11
• 238000001514 detection method Methods 0.000 description 11
• 229940079593 drug Drugs 0.000 description 11
• 239000002253 acid Substances 0.000 description 10
• 229910000085 borane Inorganic materials 0.000 description 10
• 210000004027 cell Anatomy 0.000 description 10
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 10
• 239000010949 copper Substances 0.000 description 10
• 230000004064 dysfunction Effects 0.000 description 10
• 206010022437 insomnia Diseases 0.000 description 10
• 239000012074 organic phase Substances 0.000 description 10
• 239000012071 phase Substances 0.000 description 10
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 230000003542 behavioural effect Effects 0.000 description 9
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
• 208000010877 cognitive disease Diseases 0.000 description 9
• 230000002829 reductive effect Effects 0.000 description 9
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
• LSXCLMMIDIVSFG-UHFFFAOYSA-N 3-benzylmorpholine Chemical class C=1C=CC=CC=1CC1COCCN1 LSXCLMMIDIVSFG-UHFFFAOYSA-N 0.000 description 8
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 8
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
• 241000700159 Rattus Species 0.000 description 8
• 230000037007 arousal Effects 0.000 description 8
• 229910052802 copper Inorganic materials 0.000 description 8
• VSEAAEQOQBMPQF-UHFFFAOYSA-N morpholin-3-one Chemical compound O=C1COCCN1 VSEAAEQOQBMPQF-UHFFFAOYSA-N 0.000 description 8
• 230000000446 orexinergic effect Effects 0.000 description 8
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
• 208000028173 post-traumatic stress disease Diseases 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 238000006722 reduction reaction Methods 0.000 description 8
• DAQSBVNCJRPPAZ-MRVPVSSYSA-N (2r)-2-amino-3-(5-bromo-2-fluorophenyl)propan-1-ol Chemical compound OC[C@H](N)CC1=CC(Br)=CC=C1F DAQSBVNCJRPPAZ-MRVPVSSYSA-N 0.000 description 7
• 239000005557 antagonist Substances 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 230000000694 effects Effects 0.000 description 7
• 230000013016 learning Effects 0.000 description 7
• 229910052751 metal Inorganic materials 0.000 description 7
• 239000002184 metal Substances 0.000 description 7
• 229910052763 palladium Inorganic materials 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 6
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
• 208000024827 Alzheimer disease Diseases 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 206010026749 Mania Diseases 0.000 description 6
• 208000008589 Obesity Diseases 0.000 description 6
• 238000006069 Suzuki reaction reaction Methods 0.000 description 6
• 239000012317 TBTU Substances 0.000 description 6
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 6
• 229940025084 amphetamine Drugs 0.000 description 6
• 230000036528 appetite Effects 0.000 description 6
• 235000019789 appetite Nutrition 0.000 description 6
• 238000006254 arylation reaction Methods 0.000 description 6
• 238000004296 chiral HPLC Methods 0.000 description 6
• 230000001276 controlling effect Effects 0.000 description 6
• 235000014632 disordered eating Nutrition 0.000 description 6
• 235000013305 food Nutrition 0.000 description 6
• 235000020824 obesity Nutrition 0.000 description 6
• 239000003921 oil Substances 0.000 description 6
• 208000020016 psychiatric disease Diseases 0.000 description 6
• NGKGNTQGOBQMPU-GOSISDBHSA-N tert-butyl (3R)-3-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1Cc1cccc(c1)B1OC(C)(C)C(C)(C)O1 NGKGNTQGOBQMPU-GOSISDBHSA-N 0.000 description 6
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 5
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 5
• VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
• 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 5
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
• 208000030814 Eating disease Diseases 0.000 description 5
• 102000008834 Orexin receptor Human genes 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 238000010171 animal model Methods 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 5
• 239000003054 catalyst Substances 0.000 description 5
• 229960003920 cocaine Drugs 0.000 description 5
• 230000007787 long-term memory Effects 0.000 description 5
• 208000024714 major depressive disease Diseases 0.000 description 5
• 230000004630 mental health Effects 0.000 description 5
• 210000002569 neuron Anatomy 0.000 description 5
• 229910000027 potassium carbonate Inorganic materials 0.000 description 5
• 235000015320 potassium carbonate Nutrition 0.000 description 5
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 5
• 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 5
• 239000011550 stock solution Substances 0.000 description 5
• 208000011117 substance-related disease Diseases 0.000 description 5
• RNOKFZIPFZZIAU-UHFFFAOYSA-N (2-fluoro-5-iodophenyl)methanol Chemical compound OCC1=CC(I)=CC=C1F RNOKFZIPFZZIAU-UHFFFAOYSA-N 0.000 description 4
• OBSJNTGOXQHQRF-SECBINFHSA-N (2R)-2-amino-3-(3-iodophenyl)propan-1-ol Chemical compound N[C@@H](CO)Cc1cccc(I)c1 OBSJNTGOXQHQRF-SECBINFHSA-N 0.000 description 4
• FMJRAEYLUBSWEY-DDWIOCJRSA-N (2r)-2-amino-3-(3-iodophenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@H](N)CC1=CC=CC(I)=C1 FMJRAEYLUBSWEY-DDWIOCJRSA-N 0.000 description 4
• NEMGRSGEAMFLRV-GFCCVEGCSA-N (5R)-5-[(3-pyrazol-1-ylphenyl)methyl]morpholin-3-one Chemical compound O=C1COC[C@@H](Cc2cccc(c2)-n2cccn2)N1 NEMGRSGEAMFLRV-GFCCVEGCSA-N 0.000 description 4
• BKGWUIPRQDBKPY-SNVBAGLBSA-N (5R)-5-[(4-methoxyphenyl)methyl]morpholin-3-one Chemical compound COc1ccc(C[C@@H]2COCC(=O)N2)cc1 BKGWUIPRQDBKPY-SNVBAGLBSA-N 0.000 description 4
• QRSUCLRXIYIEMG-LLVKDONJSA-N (5R)-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound O=C1COC[C@@H](Cc2cccc(c2)-n2nccn2)N1 QRSUCLRXIYIEMG-LLVKDONJSA-N 0.000 description 4
• YSSWCSYAQLKZNM-UHFFFAOYSA-N 2-(bromomethyl)-1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1CBr YSSWCSYAQLKZNM-UHFFFAOYSA-N 0.000 description 4
• XPIYCJXPRMNVBU-UHFFFAOYSA-N 2-amino-3-(3-iodophenyl)-2-methylpropan-1-ol Chemical compound OCC(N)(C)CC1=CC=CC(I)=C1 XPIYCJXPRMNVBU-UHFFFAOYSA-N 0.000 description 4
• JEQDSBVHLKBEIZ-UHFFFAOYSA-N 2-chloropropanoyl chloride Chemical compound CC(Cl)C(Cl)=O JEQDSBVHLKBEIZ-UHFFFAOYSA-N 0.000 description 4
• BMIBJCFFZPYJHF-UHFFFAOYSA-N 2-methoxy-5-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(C)C=C1B1OC(C)(C)C(C)(C)O1 BMIBJCFFZPYJHF-UHFFFAOYSA-N 0.000 description 4
• HGYHUVMZENZKHP-GOSISDBHSA-N 3-[[(3r)-4-[2-(triazol-2-yl)benzoyl]morpholin-3-yl]methyl]benzonitrile Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C1=CC=CC(C#N)=C1 HGYHUVMZENZKHP-GOSISDBHSA-N 0.000 description 4
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 4
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
• 208000032841 Bulimia Diseases 0.000 description 4
• 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 4
• 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 4
• 206010013980 Dyssomnias Diseases 0.000 description 4
• 208000011688 Generalised anxiety disease Diseases 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
• 208000006199 Parasomnias Diseases 0.000 description 4
• 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
• MWQQCNMKVRYDIW-HXUWFJFHSA-N [(3R)-3-[[4-methoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound COc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1B1OC(C)(C)C(C)(C)O1 MWQQCNMKVRYDIW-HXUWFJFHSA-N 0.000 description 4
• 230000002378 acidificating effect Effects 0.000 description 4
• 150000001502 aryl halides Chemical class 0.000 description 4
• 230000006399 behavior Effects 0.000 description 4
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical class BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
• 208000014679 binge eating disease Diseases 0.000 description 4
• 229940098773 bovine serum albumin Drugs 0.000 description 4
• 229910052794 bromium Inorganic materials 0.000 description 4
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
• 230000001143 conditioned effect Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000006735 deficit Effects 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
• 230000002996 emotional effect Effects 0.000 description 4
• SJTBTXPLPLGEJF-UHFFFAOYSA-N ethyl 2-amino-3-(3-iodophenyl)-2-methylpropanoate Chemical compound CCOC(=O)C(C)(N)CC1=CC=CC(I)=C1 SJTBTXPLPLGEJF-UHFFFAOYSA-N 0.000 description 4
• 235000012631 food intake Nutrition 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 208000029364 generalized anxiety disease Diseases 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 230000014759 maintenance of location Effects 0.000 description 4
• 238000004949 mass spectrometry Methods 0.000 description 4
• OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 4
• 238000002953 preparative HPLC Methods 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 108090000765 processed proteins & peptides Proteins 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
• 229910000104 sodium hydride Inorganic materials 0.000 description 4
• PFQDUEALMWRBLG-MRXNPFEDSA-N tert-butyl N-[(2R)-1-(2-oxopropoxy)-3-[3-(triazol-2-yl)phenyl]propan-2-yl]carbamate Chemical compound CC(=O)COC[C@@H](Cc1cccc(c1)-n1nccn1)NC(=O)OC(C)(C)C PFQDUEALMWRBLG-MRXNPFEDSA-N 0.000 description 4
• PSCAGVVDAZMIMQ-GFCCVEGCSA-N tert-butyl N-[(2R)-1-hydroxy-3-(3-iodophenyl)propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)Cc1cccc(I)c1 PSCAGVVDAZMIMQ-GFCCVEGCSA-N 0.000 description 4
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
• 239000003039 volatile agent Substances 0.000 description 4
• SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
• NMQFFSLJUVKVNT-ZOWNYOTGSA-N (2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidine;hydrochloride Chemical compound Cl.C=1C=CC(N2N=CC=N2)=CC=1C[C@@H]1CCCCN1 NMQFFSLJUVKVNT-ZOWNYOTGSA-N 0.000 description 3
• FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 3
• TYWGXVSIWUAVQS-UHFFFAOYSA-N 2-(triazol-2-yl)benzamide Chemical compound NC(=O)C1=CC=CC=C1N1N=CC=N1 TYWGXVSIWUAVQS-UHFFFAOYSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• PGFIHORVILKHIA-UHFFFAOYSA-N 2-bromopyrimidine Chemical compound BrC1=NC=CC=N1 PGFIHORVILKHIA-UHFFFAOYSA-N 0.000 description 3
• XSQPATTVZNLZJE-UHFFFAOYSA-N 3-(triazol-2-yl)pyridine-2-carboxamide Chemical class NC(=O)C1=NC=CC=C1N1N=CC=N1 XSQPATTVZNLZJE-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
• 208000020925 Bipolar disease Diseases 0.000 description 3
• 206010006550 Bulimia nervosa Diseases 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
• 239000007821 HATU Substances 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 239000012981 Hank's balanced salt solution Substances 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• 229930182821 L-proline Natural products 0.000 description 3
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 108090000189 Neuropeptides Proteins 0.000 description 3
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
• 108050000742 Orexin Receptor Proteins 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 208000005793 Restless legs syndrome Diseases 0.000 description 3
• 206010070834 Sensitisation Diseases 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• RDSLXYSTWOTMMZ-HXUWFJFHSA-N [(3R)-3-[(4-methyl-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound CC1=C(C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C1)C1=NC=CC=N1 RDSLXYSTWOTMMZ-HXUWFJFHSA-N 0.000 description 3
• 230000032683 aging Effects 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• 150000001414 amino alcohols Chemical class 0.000 description 3
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
• 230000003001 depressive effect Effects 0.000 description 3
• 238000010511 deprotection reaction Methods 0.000 description 3
• 229910052805 deuterium Inorganic materials 0.000 description 3
• WEOSHBZRDUVWAK-UHFFFAOYSA-N diethyl 2-[(2-fluoro-5-iodophenyl)methyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanedioate Chemical compound CC(C)(C)OC(=O)NC(C(=O)OCC)(C(=O)OCC)CC1=CC(I)=CC=C1F WEOSHBZRDUVWAK-UHFFFAOYSA-N 0.000 description 3
• 230000003467 diminishing effect Effects 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 230000019439 energy homeostasis Effects 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 239000012894 fetal calf serum Substances 0.000 description 3
• 239000000706 filtrate Substances 0.000 description 3
• 230000037406 food intake Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000005056 memory consolidation Effects 0.000 description 3
• 229960002715 nicotine Drugs 0.000 description 3
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
• 229940125636 orexin 1 receptor antagonist Drugs 0.000 description 3
• JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
• 208000023515 periodic limb movement disease Diseases 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 229960002429 proline Drugs 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000008313 sensitization Effects 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• PDUFXEXGHKEDET-OAHLLOKOSA-N tert-butyl (5R)-3-oxo-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1[C@H](Cc2cccc(c2)-n2nccn2)COCC1=O PDUFXEXGHKEDET-OAHLLOKOSA-N 0.000 description 3
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 3
• 229960003604 testosterone Drugs 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 238000000844 transformation Methods 0.000 description 3
• ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
• 239000003643 water by type Substances 0.000 description 3
• 229910052725 zinc Inorganic materials 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• FPSWQQMPSWZLDR-UKRRQHHQSA-N (2R,5R)-2-ethyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C(C)[C@@H]1CN[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1 FPSWQQMPSWZLDR-UKRRQHHQSA-N 0.000 description 2
• VCAFOIGCMDSJPQ-ZYHUDNBSSA-N (2R,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@@H]1C(N[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)=O VCAFOIGCMDSJPQ-ZYHUDNBSSA-N 0.000 description 2
• KDCNSORPXSBMLO-DGCLKSJQSA-N (2R,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@@H]1CN[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1 KDCNSORPXSBMLO-DGCLKSJQSA-N 0.000 description 2
• PNHSUFMWROINQD-GBWFEORMSA-N (2R,5R)-5-[(2-fluoro-5-pyridazin-3-ylphenyl)methyl]-2-methylmorpholine hydrochloride Chemical compound Cl.FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)C=1N=NC=CC1 PNHSUFMWROINQD-GBWFEORMSA-N 0.000 description 2
• RXWZYWHULZPLGO-GBWFEORMSA-N (2R,5R)-5-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]-2-methylmorpholine hydrochloride Chemical compound Cl.FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)C1=NC=CC=N1 RXWZYWHULZPLGO-GBWFEORMSA-N 0.000 description 2
• PXUCZFWUGIYYMY-ZYHUDNBSSA-N (2R,5R)-5-[[2-fluoro-5-(triazol-1-yl)phenyl]methyl]-2-methylmorpholine Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)N1N=NC=C1 PXUCZFWUGIYYMY-ZYHUDNBSSA-N 0.000 description 2
• CRXYATAKVBIIQM-ZYHUDNBSSA-N (2R,5R)-5-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]-2-methylmorpholine Chemical compound FC1=C(C[C@@H]2CO[C@@H](CN2)C)C=C(C=C1)N1N=CC=N1 CRXYATAKVBIIQM-ZYHUDNBSSA-N 0.000 description 2
• VCAFOIGCMDSJPQ-CMPLNLGQSA-N (2S,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@H]1C(N[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1)=O VCAFOIGCMDSJPQ-CMPLNLGQSA-N 0.000 description 2
• KDCNSORPXSBMLO-WCQYABFASA-N (2S,5R)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@H]1CN[C@@H](CO1)CC1=CC(=CC=C1)N1N=CC=N1 KDCNSORPXSBMLO-WCQYABFASA-N 0.000 description 2
• GVLHBFBFUSPHJO-SECBINFHSA-N (2r)-2-amino-3-(4-methoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(C[C@@H](N)CO)C=C1 GVLHBFBFUSPHJO-SECBINFHSA-N 0.000 description 2
• MPTBEGFNTNOLNZ-LLVKDONJSA-N (2r)-3-(3-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC(I)=C1 MPTBEGFNTNOLNZ-LLVKDONJSA-N 0.000 description 2
• LBXCDFQUXUGIFR-YZUKSGEXSA-N (2r,3r)-3-amino-4-(3-iodophenyl)butan-2-ol;hydrochloride Chemical compound Cl.C[C@@H](O)[C@H](N)CC1=CC=CC(I)=C1 LBXCDFQUXUGIFR-YZUKSGEXSA-N 0.000 description 2
• BJTWKCPVKGFTJA-XRZFDKQNSA-N (2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholine;hydrochloride Chemical compound Cl.C1O[C@H](C)CN[C@@H]1CC1=CC=CC(C=2N=CC=CN=2)=C1 BJTWKCPVKGFTJA-XRZFDKQNSA-N 0.000 description 2
• HUOYGRNYKOUAFE-QMMMGPOBSA-N (2s)-2-(iodoamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](NI)CC1=CC=CC=C1 HUOYGRNYKOUAFE-QMMMGPOBSA-N 0.000 description 2
• OBSJNTGOXQHQRF-VIFPVBQESA-N (2s)-2-amino-3-(3-iodophenyl)propan-1-ol Chemical compound OC[C@@H](N)CC1=CC=CC(I)=C1 OBSJNTGOXQHQRF-VIFPVBQESA-N 0.000 description 2
• FMJRAEYLUBSWEY-QRPNPIFTSA-N (2s)-2-amino-3-(3-iodophenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=CC(I)=C1 FMJRAEYLUBSWEY-QRPNPIFTSA-N 0.000 description 2
• LPQFBTXUYYZFFE-BTQNPOSSSA-N (3R)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholine hydrochloride Chemical compound Cl.FC1=C(C[C@H]2NCCOC2)C=C(C=C1)C1=NC=CC=N1 LPQFBTXUYYZFFE-BTQNPOSSSA-N 0.000 description 2
• WNUFHOFTRCYWQA-LLVKDONJSA-N (3R)-3-[(3-iodophenyl)methyl]morpholine Chemical compound Ic1cccc(C[C@@H]2COCCN2)c1 WNUFHOFTRCYWQA-LLVKDONJSA-N 0.000 description 2
• VEPVTYYJXDBEML-CYBMUJFWSA-N (3R)-3-[(3-pyrazol-1-ylphenyl)methyl]morpholine Chemical compound N1(N=CC=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 VEPVTYYJXDBEML-CYBMUJFWSA-N 0.000 description 2
• YMKJMDYWOLXDAL-CQSZACIVSA-N (3R)-3-[(3-pyrrol-1-ylphenyl)methyl]morpholine Chemical compound N1(C=CC=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 YMKJMDYWOLXDAL-CQSZACIVSA-N 0.000 description 2
• MQFACFCCESWLPF-CYBMUJFWSA-N (3R)-3-[(4-methoxy-3-pyrazol-1-ylphenyl)methyl]morpholine Chemical compound COC1=C(C=C(C[C@H]2NCCOC2)C=C1)N1N=CC=C1 MQFACFCCESWLPF-CYBMUJFWSA-N 0.000 description 2
• GUEULQXXZJJPGH-LLVKDONJSA-N (3R)-3-[(4-methoxyphenyl)methyl]morpholine Chemical compound COC1=CC=C(C[C@H]2NCCOC2)C=C1 GUEULQXXZJJPGH-LLVKDONJSA-N 0.000 description 2
• QPBOIWWCOGQZTE-UTONKHPSSA-N (3R)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine hydrochloride Chemical compound Cl.O1N=C(N=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 QPBOIWWCOGQZTE-UTONKHPSSA-N 0.000 description 2
• UNMBVMNZQKTVKW-GFCCVEGCSA-N (3R)-3-[[3-(1,2,4-triazol-1-yl)phenyl]methyl]morpholine Chemical compound N1(N=CN=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 UNMBVMNZQKTVKW-GFCCVEGCSA-N 0.000 description 2
• ITFRPORPSQTINB-GFCCVEGCSA-N (3R)-3-[[3-(triazol-1-yl)phenyl]methyl]morpholine Chemical compound N1(N=NC=C1)C=1C=C(C[C@H]2NCCOC2)C=CC1 ITFRPORPSQTINB-GFCCVEGCSA-N 0.000 description 2
• NWHWYMIXXIXEKN-GFCCVEGCSA-N (3R)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound N=1N(N=CC1)C=1C=C(C[C@H]2NCCOC2)C=CC1 NWHWYMIXXIXEKN-GFCCVEGCSA-N 0.000 description 2
• GDXQYBYOCGKOQW-DGCLKSJQSA-N (3R,5R)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@H]1N[C@@H](COC1)CC1=CC(=CC=C1)N1N=CC=N1 GDXQYBYOCGKOQW-DGCLKSJQSA-N 0.000 description 2
• GDXQYBYOCGKOQW-WCQYABFASA-N (3S,5R)-3-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C[C@@H]1N[C@@H](COC1)CC1=CC(=CC=C1)N1N=CC=N1 GDXQYBYOCGKOQW-WCQYABFASA-N 0.000 description 2
• OYVIFLMZUOOUOL-LURJTMIESA-N (3as)-3,3a,4,5,6,7-hexahydrooxathiazolo[3,4-a]pyridine 1,1-dioxide Chemical compound C1CCCN2S(=O)(=O)OC[C@@H]21 OYVIFLMZUOOUOL-LURJTMIESA-N 0.000 description 2
• WFFHPXGNIIMFHE-YFKPBYRVSA-N (3as)-3a,4,5,6-tetrahydro-3h-pyrrolo[1,2-c]oxathiazole 1,1-dioxide Chemical compound C1CCN2S(=O)(=O)OC[C@@H]21 WFFHPXGNIIMFHE-YFKPBYRVSA-N 0.000 description 2
• LQKSBIQGKSMREW-BTQNPOSSSA-N (3r)-3-[(2-fluoro-5-pyridazin-3-ylphenyl)methyl]morpholine;hydrochloride Chemical compound Cl.FC1=CC=C(C=2N=NC=CC=2)C=C1C[C@@H]1COCCN1 LQKSBIQGKSMREW-BTQNPOSSSA-N 0.000 description 2
• QRGQHRZLDVKJMS-CQSZACIVSA-N (3r)-3-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholine Chemical compound CC1=CC=C(N2N=CC=C2)C=C1C[C@@H]1COCCN1 QRGQHRZLDVKJMS-CQSZACIVSA-N 0.000 description 2
• DLSXYTDCIWMJGX-RFVHGSKJSA-N (3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.FC1=CC=C(C2=NOC=N2)C=C1C[C@@H]1COCCN1 DLSXYTDCIWMJGX-RFVHGSKJSA-N 0.000 description 2
• LKGSUFULHOJHOS-RFVHGSKJSA-N (3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C2=NOC=N2)C(OC)=CC=C1C[C@@H]1COCCN1 LKGSUFULHOJHOS-RFVHGSKJSA-N 0.000 description 2
• NWHWYMIXXIXEKN-LBPRGKRZSA-N (3s)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C=1C=CC(N2N=CC=N2)=CC=1C[C@H]1COCCN1 NWHWYMIXXIXEKN-LBPRGKRZSA-N 0.000 description 2
• LJOTZPHEEZQVMQ-CYBMUJFWSA-N (5R)-5-[(2-methyl-5-pyrazol-1-ylphenyl)methyl]morpholin-3-one Chemical compound CC1=C(C[C@@H]2COCC(N2)=O)C=C(C=C1)N1N=CC=C1 LJOTZPHEEZQVMQ-CYBMUJFWSA-N 0.000 description 2
• OBBREAYWJPJKLV-SNVBAGLBSA-N (5R)-5-[(3-iodophenyl)methyl]morpholin-3-one Chemical compound Ic1cccc(C[C@@H]2COCC(=O)N2)c1 OBBREAYWJPJKLV-SNVBAGLBSA-N 0.000 description 2
• WCXVRKZHEBZRAM-CYBMUJFWSA-N (5R)-5-[(3-pyrrol-1-ylphenyl)methyl]morpholin-3-one Chemical compound N1(C=CC=C1)C=1C=C(C[C@@H]2COCC(N2)=O)C=CC1 WCXVRKZHEBZRAM-CYBMUJFWSA-N 0.000 description 2
• NQACIJHRJOLDFZ-GFCCVEGCSA-N (5R)-5-[(4-methoxy-3-pyrazol-1-ylphenyl)methyl]morpholin-3-one Chemical compound COC1=C(C=C(C[C@@H]2COCC(N2)=O)C=C1)N1N=CC=C1 NQACIJHRJOLDFZ-GFCCVEGCSA-N 0.000 description 2
• GVZWZOWAVZFUOC-LLVKDONJSA-N (5R)-5-[[3-(1,2,4-triazol-1-yl)phenyl]methyl]morpholin-3-one Chemical compound N1(N=CN=C1)C=1C=C(C[C@@H]2COCC(N2)=O)C=CC1 GVZWZOWAVZFUOC-LLVKDONJSA-N 0.000 description 2
• URKDLMUEFQSTGX-LLVKDONJSA-N (5R)-5-[[3-(triazol-1-yl)phenyl]methyl]morpholin-3-one Chemical compound N1(N=NC=C1)C=1C=C(C[C@@H]2COCC(N2)=O)C=CC1 URKDLMUEFQSTGX-LLVKDONJSA-N 0.000 description 2
• QRSUCLRXIYIEMG-NSHDSACASA-N (5s)-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound N1C(=O)COC[C@@H]1CC1=CC=CC(N2N=CC=N2)=C1 QRSUCLRXIYIEMG-NSHDSACASA-N 0.000 description 2
• SFPQFQUXAJOWNF-UHFFFAOYSA-N 1,3-diiodobenzene Chemical compound IC1=CC=CC(I)=C1 SFPQFQUXAJOWNF-UHFFFAOYSA-N 0.000 description 2
• QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 2
• JSQVAYFVQPDRES-UHFFFAOYSA-N 2-(triazol-2-yl)-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=C1N1N=CC=N1 JSQVAYFVQPDRES-UHFFFAOYSA-N 0.000 description 2
• UTENUPFWBIFKPW-UHFFFAOYSA-N 2-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1N1N=CC=N1 UTENUPFWBIFKPW-UHFFFAOYSA-N 0.000 description 2
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
• VPNWKPSTJOTTHA-UHFFFAOYSA-N 2-bromo-3,5-dimethylbenzoic acid Chemical compound CC1=CC(C)=C(Br)C(C(O)=O)=C1 VPNWKPSTJOTTHA-UHFFFAOYSA-N 0.000 description 2
• ATBGJJWZVUNYOV-UHFFFAOYSA-N 2-bromo-4-chloro-5-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=C(Br)C=C1Cl ATBGJJWZVUNYOV-UHFFFAOYSA-N 0.000 description 2
• HECJSMILDFGZPA-UHFFFAOYSA-N 2-bromo-4-fluoro-5-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=C(Br)C=C1F HECJSMILDFGZPA-UHFFFAOYSA-N 0.000 description 2
• HNZPWRMQSCEGCM-SNVBAGLBSA-N 2-chloro-N-[(2R)-1-hydroxy-3-(4-methoxyphenyl)propan-2-yl]acetamide Chemical compound ClCC(=O)N[C@H](CC1=CC=C(C=C1)OC)CO HNZPWRMQSCEGCM-SNVBAGLBSA-N 0.000 description 2
• BNWIEYDZOIMYMJ-JTQLQIEISA-N 2-chloro-N-[(2S)-1-hydroxy-3-(3-iodophenyl)propan-2-yl]acetamide Chemical compound ClCC(=O)N[C@@H](CC1=CC(=CC=C1)I)CO BNWIEYDZOIMYMJ-JTQLQIEISA-N 0.000 description 2
• CXYWXLUYCHDQCN-UHFFFAOYSA-N 2-fluoro-3-methyl-6-(triazol-2-yl)benzoic acid Chemical compound OC(=O)C1=C(F)C(C)=CC=C1N1N=CC=N1 CXYWXLUYCHDQCN-UHFFFAOYSA-N 0.000 description 2
• ZDZURTUFHPRITG-UHFFFAOYSA-N 3-(2-fluoro-5-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC(I)=CC=C1F ZDZURTUFHPRITG-UHFFFAOYSA-N 0.000 description 2
• XYZXHNMZDYOBPV-LJQANCHMSA-N 3-[[(3r)-4-[5-methyl-2-(triazol-2-yl)benzoyl]morpholin-3-yl]methyl]benzonitrile Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C1=CC=CC(C#N)=C1 XYZXHNMZDYOBPV-LJQANCHMSA-N 0.000 description 2
• HKTWUZULWRUEBY-UHFFFAOYSA-N 3-[[4-chloro-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C2=NOC=N2)C(Cl)=CC=C1CC1COCCN1 HKTWUZULWRUEBY-UHFFFAOYSA-N 0.000 description 2
• KYPYOTZDMHPCLT-UHFFFAOYSA-N 3-[[4-methyl-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine;hydrochloride Chemical compound Cl.C1=C(C2=NOC=N2)C(C)=CC=C1CC1COCCN1 KYPYOTZDMHPCLT-UHFFFAOYSA-N 0.000 description 2
• BYTQKOCSGGRTSI-UHFFFAOYSA-N 3-bromopyridazin-1-ium;bromide Chemical compound Br.BrC1=CC=CN=N1 BYTQKOCSGGRTSI-UHFFFAOYSA-N 0.000 description 2
• IBQJAAIBLGSGSO-UHFFFAOYSA-N 3-methyl-2-(triazol-2-yl)benzoic acid Chemical compound CC1=CC=CC(C(O)=O)=C1N1N=CC=N1 IBQJAAIBLGSGSO-UHFFFAOYSA-N 0.000 description 2
• GPRNFRKRRJNJHJ-UHFFFAOYSA-N 3-methyl-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine Chemical compound C=1C=CC(N2N=CC=N2)=CC=1CC1(C)COCCN1 GPRNFRKRRJNJHJ-UHFFFAOYSA-N 0.000 description 2
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
• NBUCTPRBIWLUEC-UHFFFAOYSA-N 5-chloro-4-methyl-2-(triazol-2-yl)benzoic acid Chemical compound C1=C(Cl)C(C)=CC(N2N=CC=N2)=C1C(O)=O NBUCTPRBIWLUEC-UHFFFAOYSA-N 0.000 description 2
• CJVLMNWLOGOOGB-UHFFFAOYSA-N 5-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C=1C=CC(N2N=CC=N2)=CC=1CC1(C)COCC(=O)N1 CJVLMNWLOGOOGB-UHFFFAOYSA-N 0.000 description 2
• 241000349731 Afzelia bipindensis Species 0.000 description 2
• 208000000103 Anorexia Nervosa Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010004716 Binge eating Diseases 0.000 description 2
• 208000021500 Breathing-related sleep disease Diseases 0.000 description 2
• 206010006895 Cachexia Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
• 206010012289 Dementia Diseases 0.000 description 2
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• 101000598921 Homo sapiens Orexin Proteins 0.000 description 2
• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
• 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
• 201000002832 Lewy body dementia Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 206010027944 Mood disorder due to a general medical condition Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
• PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 102000003797 Neuropeptides Human genes 0.000 description 2
• 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 206010033664 Panic attack Diseases 0.000 description 2
• 206010062519 Poor quality sleep Diseases 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
• 206010041250 Social phobia Diseases 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• 208000011962 Substance-induced mood disease Diseases 0.000 description 2
• 231100000395 Substance-induced mood disorder Toxicity 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• PRAYXGYYVXRDDW-LURJTMIESA-N [(2s)-piperidin-2-yl]methanol Chemical compound OC[C@@H]1CCCCN1 PRAYXGYYVXRDDW-LURJTMIESA-N 0.000 description 2
• OBGUWOPMHXCGQJ-GOSISDBHSA-N [(3R)-3-[(4-hydroxy-3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound Oc1ccc(C[C@@H]2COCCN2C(=O)c2ccccc2-n2nccn2)cc1-c1ncccn1 OBGUWOPMHXCGQJ-GOSISDBHSA-N 0.000 description 2
• UZGKFZMOPJQKAA-QGZVFWFLSA-N [(3R)-3-[(4-methoxyphenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound COC1=CC=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=C1 UZGKFZMOPJQKAA-QGZVFWFLSA-N 0.000 description 2
• RFRBKJBYJXZXKQ-LJQANCHMSA-N [(3r)-3-[[4-methyl-3-(1,3-thiazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@H]1CC2=CC=C(C(=C2)C=2SC=CN=2)C)OCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 RFRBKJBYJXZXKQ-LJQANCHMSA-N 0.000 description 2
• OBJHSZWESOSYIS-IBGZPJMESA-N [2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidin-1-yl]methanone Chemical compound C([C@@H]1CCCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 OBJHSZWESOSYIS-IBGZPJMESA-N 0.000 description 2
• OFOKYTZDYMGETB-SFHVURJKSA-N [2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidin-1-yl]methanone Chemical compound C([C@@H]1CCCN1C(=O)C=1C(=CC=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 OFOKYTZDYMGETB-SFHVURJKSA-N 0.000 description 2
• ORFRNFXCPZMBSM-UHFFFAOYSA-N [3-[[4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(CC2N(CCOC2)C(=O)C=2C(=CC=CC=2)N2N=CC=N2)=CC=C1Cl ORFRNFXCPZMBSM-UHFFFAOYSA-N 0.000 description 2
• TYEDLXWBPOOACY-UHFFFAOYSA-N [3-[[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound C1=C(B2OC(C)(C)C(C)(C)O2)C(C)=CC=C1CC1COCCN1C(=O)C1=CC=CC=C1N1N=CC=N1 TYEDLXWBPOOACY-UHFFFAOYSA-N 0.000 description 2
• VYUBRYYCCNWARR-FQEVSTJZSA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidin-1-yl]methanone Chemical compound C([C@@H]1CCCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 VYUBRYYCCNWARR-FQEVSTJZSA-N 0.000 description 2
• PQIZGRDRKSOBSA-IBGZPJMESA-N [5-methyl-2-(triazol-2-yl)phenyl]-[(2s)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidin-1-yl]methanone Chemical compound C([C@@H]1CCCN1C(=O)C=1C(=CC=C(C=1)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 PQIZGRDRKSOBSA-IBGZPJMESA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 230000006389 acute stress response Effects 0.000 description 2
• 230000010933 acylation Effects 0.000 description 2
• 238000005917 acylation reaction Methods 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 229960003767 alanine Drugs 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• UDGDHNGWPNSYCD-ZDUSSCGKSA-N benzyl (2s)-2-(hydroxymethyl)piperidine-1-carboxylate Chemical compound OC[C@@H]1CCCCN1C(=O)OCC1=CC=CC=C1 UDGDHNGWPNSYCD-ZDUSSCGKSA-N 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 230000002060 circadian Effects 0.000 description 2
• 229940125904 compound 1 Drugs 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 229940126214 compound 3 Drugs 0.000 description 2
• 238000007596 consolidation process Methods 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
• 230000004665 defense response Effects 0.000 description 2
• 230000000994 depressogenic effect Effects 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• 229960003638 dopamine Drugs 0.000 description 2
• 230000035622 drinking Effects 0.000 description 2
• 230000002526 effect on cardiovascular system Effects 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000008451 emotion Effects 0.000 description 2
• 230000001073 episodic memory Effects 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• AQGWAQNSCSFLPR-UHFFFAOYSA-N ethyl 2-(2,2-dimethylpropylideneamino)propanoate Chemical compound CCOC(=O)C(C)N=CC(C)(C)C AQGWAQNSCSFLPR-UHFFFAOYSA-N 0.000 description 2
• 230000000763 evoking effect Effects 0.000 description 2
• 230000004634 feeding behavior Effects 0.000 description 2
• 239000012065 filter cake Substances 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 238000011813 knockout mouse model Methods 0.000 description 2
• IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 2
• 210000001853 liver microsome Anatomy 0.000 description 2
• 230000003137 locomotive effect Effects 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 208000004296 neuralgia Diseases 0.000 description 2
• 208000021722 neuropathic pain Diseases 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 210000001009 nucleus accumben Anatomy 0.000 description 2
• OHOWSYIKESXDMN-WMQZXSDYSA-N orexin-b Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCSC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O)C1=CNC=N1 OHOWSYIKESXDMN-WMQZXSDYSA-N 0.000 description 2
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
• 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000003938 response to stress Effects 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 201000002859 sleep apnea Diseases 0.000 description 2
• 230000008454 sleep-wake cycle Effects 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• MDGBGGXDHQORJS-INIZCTEOSA-N tert-butyl (2s)-2-[[3-(triazol-2-yl)phenyl]methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1CC1=CC=CC(N2N=CC=N2)=C1 MDGBGGXDHQORJS-INIZCTEOSA-N 0.000 description 2
• YUNXVGBBZWRVCL-HNNXBMFYSA-N tert-butyl (2s)-2-[[3-(triazol-2-yl)phenyl]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CC1=CC=CC(N2N=CC=N2)=C1 YUNXVGBBZWRVCL-HNNXBMFYSA-N 0.000 description 2
• NVOACJCZJBLHSW-OAHLLOKOSA-N tert-butyl (3R)-3-[(3-cyano-4-methoxyphenyl)methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=C(C=C1)OC)C#N NVOACJCZJBLHSW-OAHLLOKOSA-N 0.000 description 2
• YEFYTWNFRQZKCB-OAHLLOKOSA-N tert-butyl (3R)-3-[(3-cyanophenyl)methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)C#N YEFYTWNFRQZKCB-OAHLLOKOSA-N 0.000 description 2
• MBGOPDXJAKYNOH-OAHLLOKOSA-N tert-butyl (3R)-3-[[3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine-4-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@@H](COCC1)CC1=CC(=CC=C1)C1=NOC=N1 MBGOPDXJAKYNOH-OAHLLOKOSA-N 0.000 description 2
• DEHYOXSRLODULD-QGZVFWFLSA-N tert-butyl (3r)-3-[(3-pyrimidin-2-ylphenyl)methyl]morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1CC1=CC=CC(C=2N=CC=CN=2)=C1 DEHYOXSRLODULD-QGZVFWFLSA-N 0.000 description 2
• AEPFJOKWEXQFFJ-CQSZACIVSA-N tert-butyl (3r)-3-[[4-methoxy-3-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholine-4-carboxylate Chemical compound C1=C(C2=NOC=N2)C(OC)=CC=C1C[C@@H]1COCCN1C(=O)OC(C)(C)C AEPFJOKWEXQFFJ-CQSZACIVSA-N 0.000 description 2
• RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical compound CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
• YSBGRVXJEMSEQY-DEOSSOPVSA-N (2s)-1-[2-(1-methylbenzimidazol-2-yl)sulfanylacetyl]-n-(2-phenylphenyl)pyrrolidine-2-carboxamide Chemical compound O=C([C@@H]1CCCN1C(=O)CSC=1N(C2=CC=CC=C2N=1)C)NC1=CC=CC=C1C1=CC=CC=C1 YSBGRVXJEMSEQY-DEOSSOPVSA-N 0.000 description 1
• ZSAIHAKADPJIGN-LBPRGKRZSA-N (2s)-1-phenylmethoxycarbonylpiperidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCCN1C(=O)OCC1=CC=CC=C1 ZSAIHAKADPJIGN-LBPRGKRZSA-N 0.000 description 1
• DWUNPDNAGCEMMX-LBPRGKRZSA-N (2s)-2-[(3-iodophenyl)methyl]piperidine Chemical compound IC1=CC=CC(C[C@H]2NCCCC2)=C1 DWUNPDNAGCEMMX-LBPRGKRZSA-N 0.000 description 1
• ORTYUBGXIIIBLA-NSHDSACASA-N (2s)-2-[(3-iodophenyl)methyl]pyrrolidine Chemical compound IC1=CC=CC(C[C@H]2NCCC2)=C1 ORTYUBGXIIIBLA-NSHDSACASA-N 0.000 description 1
• MPTBEGFNTNOLNZ-NSHDSACASA-N (2s)-3-(3-iodophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC(I)=C1 MPTBEGFNTNOLNZ-NSHDSACASA-N 0.000 description 1
• LBXCDFQUXUGIFR-XQRIHRDZSA-N (2s,3r)-3-amino-4-(3-iodophenyl)butan-2-ol;hydrochloride Chemical compound Cl.C[C@H](O)[C@H](N)CC1=CC=CC(I)=C1 LBXCDFQUXUGIFR-XQRIHRDZSA-N 0.000 description 1
• WDQHADONQHFXGP-SECBINFHSA-N (5R)-5-[(3-iodo-4-methoxyphenyl)methyl]morpholin-3-one Chemical compound COc1ccc(C[C@@H]2COCC(=O)N2)cc1I WDQHADONQHFXGP-SECBINFHSA-N 0.000 description 1
• NDOUDTBXCRRZRI-ZWNOBZJWSA-N (5R,6R)-6-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@H]1OCC(N[C@@H]1CC1=CC(=CC=C1)N1N=CC=N1)=O NDOUDTBXCRRZRI-ZWNOBZJWSA-N 0.000 description 1
• NDOUDTBXCRRZRI-GXFFZTMASA-N (5R,6S)-6-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-3-one Chemical compound C[C@@H]1OCC(N[C@@H]1CC1=CC(=CC=C1)N1N=CC=N1)=O NDOUDTBXCRRZRI-GXFFZTMASA-N 0.000 description 1
• POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
• BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical group C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
• 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• KDDPMKJRRPHLTE-UHFFFAOYSA-N 2-amino-2-[(2-methylpropan-2-yl)oxycarbonyl]propanedioic acid Chemical compound CC(C)(C)OC(=O)C(N)(C(O)=O)C(O)=O KDDPMKJRRPHLTE-UHFFFAOYSA-N 0.000 description 1
• BFPGCWOVXJFKPY-UHFFFAOYSA-N 2-bromo-5-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=C(Br)C=C1C BFPGCWOVXJFKPY-UHFFFAOYSA-N 0.000 description 1
• ARNFNRFSPMXZAG-GZMMTYOYSA-N 2-chloro-N-[(2R,3S)-3-hydroxy-1-(3-iodophenyl)butan-2-yl]acetamide Chemical compound ClCC(=O)N[C@@H]([C@H](C)O)CC1=CC(=CC=C1)I ARNFNRFSPMXZAG-GZMMTYOYSA-N 0.000 description 1
• KVQJVAOMYWTLEO-UHFFFAOYSA-N 2-chlorobutanoyl chloride Chemical compound CCC(Cl)C(Cl)=O KVQJVAOMYWTLEO-UHFFFAOYSA-N 0.000 description 1
• KBFVSJVSSMGQJC-UHFFFAOYSA-N 2-fluoro-3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1F KBFVSJVSSMGQJC-UHFFFAOYSA-N 0.000 description 1
• QNNJHBNTHVHALE-UHFFFAOYSA-N 2-fluoro-5-iodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC=C1F QNNJHBNTHVHALE-UHFFFAOYSA-N 0.000 description 1
• XYRLGIOIAJNDJX-UHFFFAOYSA-N 2-fluoro-6-iodo-3-methylbenzoic acid Chemical compound CC1=CC=C(I)C(C(O)=O)=C1F XYRLGIOIAJNDJX-UHFFFAOYSA-N 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• CGUFWPQURMBLMB-UHFFFAOYSA-N 2-iodo-3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC(C#N)=C1I CGUFWPQURMBLMB-UHFFFAOYSA-N 0.000 description 1
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
• UMVOQQDNEYOJOK-UHFFFAOYSA-N 3,5-dimethylbenzoic acid Chemical compound CC1=CC(C)=CC(C(O)=O)=C1 UMVOQQDNEYOJOK-UHFFFAOYSA-N 0.000 description 1
• CEAVPXDEPGAVDA-UHFFFAOYSA-N 3-methoxy-4-methylbenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1C CEAVPXDEPGAVDA-UHFFFAOYSA-N 0.000 description 1
• ZABRUMFAJKMYDU-UHFFFAOYSA-N 3-methyl-2-(triazol-2-yl)benzonitrile Chemical compound CC1=CC=CC(C#N)=C1N1N=CC=N1 ZABRUMFAJKMYDU-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• BVVSWRIBSPAQPU-HXUWFJFHSA-N 4-(triazol-2-yl)-3-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholine-4-carbonyl]benzonitrile Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1)C#N)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 BVVSWRIBSPAQPU-HXUWFJFHSA-N 0.000 description 1
• WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• OXUUNDMDOOXPKY-UHFFFAOYSA-N 4-chloro-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1Cl OXUUNDMDOOXPKY-UHFFFAOYSA-N 0.000 description 1
• LWGCZCMLPRMKIZ-UHFFFAOYSA-N 4-fluoro-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1F LWGCZCMLPRMKIZ-UHFFFAOYSA-N 0.000 description 1
• NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
• YHPJTKZGZAVEIL-UHFFFAOYSA-N 5-[(3-iodophenyl)methyl]-5-methylmorpholin-3-one Chemical compound C=1C=CC(I)=CC=1CC1(C)COCC(=O)N1 YHPJTKZGZAVEIL-UHFFFAOYSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• XSEGWEUVSZRCBC-UHFFFAOYSA-N 6beta-Hydroxytestosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC(O)C2=C1 XSEGWEUVSZRCBC-UHFFFAOYSA-N 0.000 description 1
• XSEGWEUVSZRCBC-ZVBLRVHNSA-N 6beta-hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3C[C@@H](O)C2=C1 XSEGWEUVSZRCBC-ZVBLRVHNSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
• 206010063659 Aversion Diseases 0.000 description 1
• 108010017443 B 43 Proteins 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• KTETVPXBWOHYCR-UHFFFAOYSA-N CC(C)(C)OC(=O)NC(Cc1ccc(Cl)c(I)c1)C(O)=O Chemical compound CC(C)(C)OC(=O)NC(Cc1ccc(Cl)c(I)c1)C(O)=O KTETVPXBWOHYCR-UHFFFAOYSA-N 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 208000028698 Cognitive impairment Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 206010011971 Decreased interest Diseases 0.000 description 1
• 206010012218 Delirium Diseases 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
• 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
• 208000027534 Emotional disease Diseases 0.000 description 1
• 208000010235 Food Addiction Diseases 0.000 description 1
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
• 230000005526 G1 to G0 transition Effects 0.000 description 1
• 208000001613 Gambling Diseases 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 206010020710 Hyperphagia Diseases 0.000 description 1
• 201000001916 Hypochondriasis Diseases 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 208000015814 Intrinsic Sleep disease Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000026139 Memory disease Diseases 0.000 description 1
• 208000036626 Mental retardation Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• 229910019065 NaOH 1 M Inorganic materials 0.000 description 1
• 102000028517 Neuropeptide receptor Human genes 0.000 description 1
• 108070000018 Neuropeptide receptor Proteins 0.000 description 1
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
• 208000000224 Night Terrors Diseases 0.000 description 1
• 206010029412 Nightmare Diseases 0.000 description 1
• 101150053185 P450 gene Proteins 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 206010034912 Phobia Diseases 0.000 description 1
• 206010034918 Phobic avoidance Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 241000700157 Rattus norvegicus Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 208000000810 Separation Anxiety Diseases 0.000 description 1
• 208000022249 Sleep-Wake Transition disease Diseases 0.000 description 1
• 208000027520 Somatoform disease Diseases 0.000 description 1
• 206010041347 Somnambulism Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• 231100000643 Substance intoxication Toxicity 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• HVVNJUAVDAZWCB-YFKPBYRVSA-N [(2s)-pyrrolidin-2-yl]methanol Chemical compound OC[C@@H]1CCCN1 HVVNJUAVDAZWCB-YFKPBYRVSA-N 0.000 description 1
• OGEMHFJULYOBHG-QGZVFWFLSA-N [(3R)-3-[(3-iodophenyl)methyl]morpholin-4-yl]-[2-(triazol-2-yl)phenyl]methanone Chemical compound IC=1C=C(C[C@H]2N(CCOC2)C(=O)C2=C(C=CC=C2)N2N=CC=N2)C=CC1 OGEMHFJULYOBHG-QGZVFWFLSA-N 0.000 description 1
• KJXCOZMMUXZQGE-GOSISDBHSA-N [(3R)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[2-(triazol-2-yl)-3-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)c1cccc(C(=O)N2CCOC[C@H]2Cc2cccc(c2)-n2nccn2)c1-n1nccn1 KJXCOZMMUXZQGE-GOSISDBHSA-N 0.000 description 1
• HWCNAOSLUJKVML-LJQANCHMSA-N [(3r)-3-[[2-fluoro-5-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]-[4-methyl-2-(triazol-2-yl)phenyl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C=C1N1N=CC=N1)C)C(C(=CC=1)F)=CC=1N1N=CC=N1 HWCNAOSLUJKVML-LJQANCHMSA-N 0.000 description 1
• JNZNQAZDCIXPAH-LJQANCHMSA-N [2-fluoro-3-methyl-6-(triazol-2-yl)phenyl]-[(3r)-3-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C=1C(=CC=C(C=1F)C)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 JNZNQAZDCIXPAH-LJQANCHMSA-N 0.000 description 1
• DFLPJQGANRAIIM-OAQYLSRUSA-N [3,4-dimethyl-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@@H]1COCCN1C(=O)C1=CC=C(C(=C1N1N=CC=N1)C)C)C(C(=CC=1)F)=CC=1C1=NC=CC=N1 DFLPJQGANRAIIM-OAQYLSRUSA-N 0.000 description 1
• JHVXWNVBCOMNJH-GOSISDBHSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C=2N=CC=CN=2)OCCN1C(=O)C1=CC=CC(Cl)=C1N1N=CC=N1 JHVXWNVBCOMNJH-GOSISDBHSA-N 0.000 description 1
• CGFVLVBFXFGDNF-MRXNPFEDSA-N [3-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C2=NOC=N2)OCCN1C(=O)C1=CC=CC(Cl)=C1N1N=CC=N1 CGFVLVBFXFGDNF-MRXNPFEDSA-N 0.000 description 1
• JOAYSRXNJHJJBL-DYESRHJHSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC(Cl)=CC=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 JOAYSRXNJHJJBL-DYESRHJHSA-N 0.000 description 1
• NNBZSPNSBCOMJO-LJQANCHMSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C=2N=CC=CN=2)OCCN1C(=O)C1=CC=C(Cl)C=C1N1N=CC=N1 NNBZSPNSBCOMJO-LJQANCHMSA-N 0.000 description 1
• SBDNJLCIYJRHKZ-QGZVFWFLSA-N [4-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C2=NOC=N2)OCCN1C(=O)C1=CC=C(Cl)C=C1N1N=CC=N1 SBDNJLCIYJRHKZ-QGZVFWFLSA-N 0.000 description 1
• KKGJPPRCCVZKMV-DYESRHJHSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[(3-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C=1)=CC=CC=1C1=NC=CC=N1 KKGJPPRCCVZKMV-DYESRHJHSA-N 0.000 description 1
• RWWXBFGEFGPVOA-OXQOHEQNSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(2r,5r)-2-methyl-5-[[3-(triazol-2-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1N(C[C@H](OC1)C)C(=O)C=1C(=CC=C(Cl)C=1)N1N=CC=N1)C(C=1)=CC=CC=1N1N=CC=N1 RWWXBFGEFGPVOA-OXQOHEQNSA-N 0.000 description 1
• LFTFHZCWXHYQAL-LJQANCHMSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[(2-fluoro-5-pyrimidin-2-ylphenyl)methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C=2N=CC=CN=2)OCCN1C(=O)C1=CC(Cl)=CC=C1N1N=CC=N1 LFTFHZCWXHYQAL-LJQANCHMSA-N 0.000 description 1
• GOPNUSXTFNCXKO-QGZVFWFLSA-N [5-chloro-2-(triazol-2-yl)phenyl]-[(3r)-3-[[2-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl]methyl]morpholin-4-yl]methanone Chemical compound C([C@H]1CC2=CC(=CC=C2F)C2=NOC=N2)OCCN1C(=O)C1=CC(Cl)=CC=C1N1N=CC=N1 GOPNUSXTFNCXKO-QGZVFWFLSA-N 0.000 description 1
• 208000003554 absence epilepsy Diseases 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
• QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 150000001294 alanine derivatives Chemical class 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 230000036626 alertness Effects 0.000 description 1
• 235000011114 ammonium hydroxide Nutrition 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 230000001430 anti-depressive effect Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 230000036506 anxiety Effects 0.000 description 1
• 235000021407 appetite control Nutrition 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 238000013528 artificial neural network Methods 0.000 description 1
• 230000035045 associative learning Effects 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 208000028683 bipolar I disease Diseases 0.000 description 1
• 208000022257 bipolar II disease Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• QFWACQSXKWRSLR-UHFFFAOYSA-N carboniodidic acid Chemical compound OC(I)=O QFWACQSXKWRSLR-UHFFFAOYSA-N 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 239000012320 chlorinating reagent Substances 0.000 description 1
• 238000013375 chromatographic separation Methods 0.000 description 1
• 230000037326 chronic stress Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 235000009508 confectionery Nutrition 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 235000019788 craving Nutrition 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 208000026725 cyclothymic disease Diseases 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 239000012024 dehydrating agents‎ Substances 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 201000001098 delayed sleep phase syndrome Diseases 0.000 description 1
• 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 125000004431 deuterium atom Chemical group 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
• 239000002027 dichloromethane extract Substances 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• ULRLHEXGRUWQLQ-UHFFFAOYSA-N diethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)NC(=O)OC(C)(C)C ULRLHEXGRUWQLQ-UHFFFAOYSA-N 0.000 description 1
• GLFVNTDRBTZJIY-UHFFFAOYSA-N diethyl 2-aminopropanedioate;hydron;chloride Chemical compound Cl.CCOC(=O)C(N)C(=O)OCC GLFVNTDRBTZJIY-UHFFFAOYSA-N 0.000 description 1
• 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• 230000003292 diminished effect Effects 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 206010013663 drug dependence Diseases 0.000 description 1
• 208000024732 dysthymic disease Diseases 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 230000020595 eating behavior Effects 0.000 description 1
• 239000002895 emetic Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 238000011067 equilibration Methods 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• JCXLZWMDXJFOOI-UHFFFAOYSA-N ethyl 2-aminopropanoate;hydron;chloride Chemical compound [Cl-].CCOC(=O)C(C)[NH3+] JCXLZWMDXJFOOI-UHFFFAOYSA-N 0.000 description 1
• OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 238000010304 firing Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000012632 fluorescent imaging Methods 0.000 description 1
• 239000000446 fuel Substances 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 206010020765 hypersomnia Diseases 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 210000003016 hypothalamus Anatomy 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 230000002197 limbic effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000002514 liquid chromatography mass spectrum Methods 0.000 description 1
• 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 230000033001 locomotion Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• 150000002690 malonic acid derivatives Chemical class 0.000 description 1
• 240000004308 marijuana Species 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000001819 mass spectrum Methods 0.000 description 1
• BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
• 230000007087 memory ability Effects 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 230000006386 memory function Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
• 230000003818 metabolic dysfunction Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• AYHCWHCWQSWWRE-UHFFFAOYSA-N methyl 2-bromo-5-chloro-4-methylbenzoate Chemical compound COC(=O)C1=CC(Cl)=C(C)C=C1Br AYHCWHCWQSWWRE-UHFFFAOYSA-N 0.000 description 1
• DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000000897 modulatory effect Effects 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 150000002780 morpholines Chemical class 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 229940000041 nervous system drug Drugs 0.000 description 1
• 230000006855 networking Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 229960001783 nicardipine Drugs 0.000 description 1
• 230000021363 nonassociative learning Effects 0.000 description 1
• 235000019645 odor Nutrition 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 235000020830 overeating Nutrition 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 208000019899 phobic disease Diseases 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 229960005235 piperonyl butoxide Drugs 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 206010036067 polydipsia Diseases 0.000 description 1
• 235000011056 potassium acetate Nutrition 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
• 229960003081 probenecid Drugs 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000004129 prosencephalon Anatomy 0.000 description 1
• 229940001470 psychoactive drug Drugs 0.000 description 1
• 239000004089 psychotropic agent Substances 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000006798 ring closing metathesis reaction Methods 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 208000025874 separation anxiety disease Diseases 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 230000004037 social stress Effects 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 201000001716 specific phobia Diseases 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 231100000736 substance abuse Toxicity 0.000 description 1
• 201000006152 substance dependence Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• BYAVXGJOGRCEHB-HNNXBMFYSA-N tert-butyl (2s)-2-[(3-iodophenyl)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC[C@H]1CC1=CC=CC(I)=C1 BYAVXGJOGRCEHB-HNNXBMFYSA-N 0.000 description 1
• FIVOVOOOMFAWBY-AWEZNQCLSA-N tert-butyl (2s)-2-[(3-iodophenyl)methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CC1=CC=CC(I)=C1 FIVOVOOOMFAWBY-AWEZNQCLSA-N 0.000 description 1
• NMYODLKTGUEPAQ-CQSZACIVSA-N tert-butyl (3R)-3-[(3-iodophenyl)methyl]morpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOC[C@H]1Cc1cccc(I)c1 NMYODLKTGUEPAQ-CQSZACIVSA-N 0.000 description 1
• HJYNLENYMULSAS-UHFFFAOYSA-N tert-butyl 3-oxomorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1=O HJYNLENYMULSAS-UHFFFAOYSA-N 0.000 description 1
• BVJYFSNMLDPCMF-GFCCVEGCSA-N tert-butyl N-[(2R)-1-(3-iodophenyl)-3-oxopropan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](Cc1cccc(I)c1)C=O BVJYFSNMLDPCMF-GFCCVEGCSA-N 0.000 description 1
• QLGSWXOALGVOST-GXFFZTMASA-N tert-butyl N-[(2R,3S)-3-hydroxy-1-(3-iodophenyl)butan-2-yl]carbamate Chemical compound C(C)(C)(C)OC(N[C@@H]([C@H](C)O)CC1=CC(=CC=C1)I)=O QLGSWXOALGVOST-GXFFZTMASA-N 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 230000002618 waking effect Effects 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 230000003936 working memory Effects 0.000 description 1
• XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1